NEW YORK (GenomeWeb) – CombiMatrix reported after the close of the market on Thursday a 28 percent jump in first quarter revenues, an increase driven by growing sales of both its microarray and non-microarray diagnostics tests.

For the three-month period ended March 31, CombiMatrix's revenues rose to $2.3 million from $1.8 million in the same period a year earlier, matching analysts' average estimate.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.